Hopitaux Prives De Metz — Clinical Trial Site

38 Registered trials

16 Currently recruiting

Organisation

Hopitaux Prives De Metz

Location

Vantoux, France

Identifier

ORG-100043189

Address

Rue Du Pre Montois, 57070, France

Departments

2305:Pneumologie
Cancérologie-pneumologie
Chirurgie gynécologique & sénologique
Département de Pneumologie
Internal Medicine
Médecine interne
Medical Oncology
N/A
Oncologie
Oncologie Médicale
Oncology
Oncology Unit
Pneumologie
Pneumology
Pulmonology department
Service d'Oncologie
Service de Pneumologie
Service de Réanimation Polyvalente
Service Pneumologie

Clinical trials at this site (38)

Search interface

MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending

2025-521331-36-00 Patient with stabilized SSc-ILD (as defined by a declin 10
Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending

2025-522790-10-00 Non Small Cell Lung Cancer 4
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
A study to investigate efficacy, safety, immunogenicity, and pharmacokinetics of GSK3862995B following repeat doses in participants with bro… Recruiting

2025-522892-27-00 Bronchiectasis 4 2026-03-21
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro… Recruiting

2022-501557-36-00 PR3-ANCA granulomatosis with polyangiitis (Wegener’s) 4 2025-12-19
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Evaluating ivonescimab as a potential treatment for pleural mesothelioma patients whose cancer has returned after previous immunotherapy and… Recruiting

2024-519052-82-00 pleural mesothelioma 4 2025-06-30
Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting

2024-516242-19-00 lupus nephritis 5 2024-11-05
Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting

2024-514304-14-00 Advanced or Metastatic Non-squamous Non-Small Cell Lung 1 2024-10-08
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting

2023-509761-21-00 Metastatic colorectal cancer 5 2024-07-08
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO Recruiting

2022-501057-36-00 ANCA-associated vasculitis 5 2023-10-24
EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co… Recruiting

2022-501335-16-00 Interstitial lung disease 10 2023-01-16
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting

2024-513427-17-00 Well controlled severe allergic asthma 6 2021-05-20
A multicenter, prospective, randomized, placebo-controlled, double-blind, multi-arm, multi-stage clinical trial of Ivabradine for heart Rate… Recruiting

2024-515019-22-00 Septic shock 5 2021-02-26
Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended

2024-515538-34-00 Head and Neck Squamous Cell Carcinoma 10 2025-02-27
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
TocilizuMab discontinuAtion in GIant Cell Arteritis Ended

2023-505515-21-00 Giant Cell Arteritis 5 2024-04-02
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 advanced non-squamous non-small cell lung cancer 4 2023-04-25
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03